Literature DB >> 24892266

Neuromuscular blockade during therapeutic hypothermia after cardiac arrest: observational study of neurological and infectious outcomes.

Jean Baptiste Lascarrou1, Amélie Le Gouge2, Jérome Dimet3, Jean Claude Lacherade4, Laurent Martin-Lefèvre4, Maud Fiancette4, Isabelle Vinatier4, Christine Lebert4, Konstantinos Bachoumas4, Aihem Yehia4, Matthieu Henry Lagarrigue4, Gwenhael Colin4, Jean Reignier5.   

Abstract

INTRODUCTION: Neuromuscular blockade (NMB) is widely used during therapeutic hypothermia (TH) after cardiac arrest but its effect on patient outcomes is unclear. We compared the effects of NMB on neurological outcomes and frequency of early-onset pneumonia in cardiac-arrest survivors managed with TH.
METHODS: We retrospectively studied consecutive adult cardiac-arrest survivors managed with TH in a tertiary-level intensive care unit between January 2008 and July 2013. Patients given continuous NMB for persistent shivering were compared to those managed without NMB. Cases of early-onset pneumonia and vital status at ICU discharge were recorded. To avoid bias due to between-group baseline differences, we adjusted the analysis on a propensity score.
RESULTS: Of 311 cardiac-arrest survivors, 144 received TH, including 117 with continuous NMB and 27 without NMBs. ICU mortality was lower with NMB (hazard ratio [HR], 0.54 [0.32; 0.89], p=0.016) but the difference was not significant after adjustment on the propensity score (HR, 0.70 [0.39; 1.25], p=0.22). The proportion of patients with good neurological outcomes was not significantly different (36% with and 22% without NMB, p=0.16). Early-onset pneumonia was more common with NMB (HR, 2.36 [1.24; 4.50], p=0.009) but the difference was not significant after adjustment on the propensity score (HR, 1.68 [0.90; 3.16], p=0.10).
CONCLUSIONS: Continuous intravenous NMB during TH after cardiac arrest has potential owns effects on ICU survival with a trend increase in the frequency of early-onset pneumonia. Randomised controlled trials are needed to define the role for NMB among treatments for TH-induced shivering.
Copyright © 2014 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Cardiac arrest; Induced hypothermia; Neuromuscular blockade; Pneumonia

Mesh:

Year:  2014        PMID: 24892266     DOI: 10.1016/j.resuscitation.2014.05.017

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  12 in total

1.  Coronary angiography after cardiac arrest: useful for whom?

Authors:  Jean Baptiste Lascarrou; Aurélie Le Thuaut; Gwenhael Colin; Jean Reignier
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

Review 2.  The Implementation of Targeted Temperature Management: An Evidence-Based Guideline from the Neurocritical Care Society.

Authors:  Lori Kennedy Madden; Michelle Hill; Teresa L May; Theresa Human; Mary McKenna Guanci; Judith Jacobi; Melissa V Moreda; Neeraj Badjatia
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

3.  Variation in Sedation and Neuromuscular Blockade Regimens on Outcome After Cardiac Arrest.

Authors:  Teresa L May; Richard R Riker; Gilles L Fraser; Karen G Hirsch; Sachin Agarwal; Christine Duarte; Hans Friberg; Eldar Søreide; John McPherson; Robert Hand; David Kent; Niklas Nielsen; David B Seder
Journal:  Crit Care Med       Date:  2018-10       Impact factor: 7.598

4.  Association of multiple rib fractures with the frequency of pneumonia in the post-resuscitation period.

Authors:  Yasuyuki Kawai; Keisuke Takano; Keita Miyazaki; Koji Yamamoto; Yusuke Tada; Hideki Asai; Naoki Maegawa; Yasuyuki Urisono; Keigo Saeki; Hidetada Fukushima
Journal:  Resusc Plus       Date:  2022-07-01

5.  European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care.

Authors:  Jerry P Nolan; Claudio Sandroni; Bernd W Böttiger; Alain Cariou; Tobias Cronberg; Hans Friberg; Cornelia Genbrugge; Kirstie Haywood; Gisela Lilja; Véronique R M Moulaert; Nikolaos Nikolaou; Theresa Mariero Olasveengen; Markus B Skrifvars; Fabio Taccone; Jasmeet Soar
Journal:  Intensive Care Med       Date:  2021-03-25       Impact factor: 17.440

6.  Association Between Target Temperature Variability and Neurologic Outcomes for Patients Receiving Targeted Temperature Management at 36°C After Cardiac Arrest: A Retrospective Cohort Study.

Authors:  Makayla Cordoza; Hilaire Thompson; Elizabeth Bridges; Robert Burr; David Carlbom
Journal:  Ther Hypothermia Temp Manag       Date:  2020-06-16       Impact factor: 1.369

7.  Therapeutic hypothermia after nonshockable cardiac arrest: the HYPERION multicenter, randomized, controlled, assessor-blinded, superiority trial.

Authors:  Jean Baptiste Lascarrou; Ferhat Meziani; Amélie Le Gouge; Thierry Boulain; Jérôme Bousser; Guillaume Belliard; Pierre Asfar; Jean Pierre Frat; Pierre François Dequin; Jean Paul Gouello; Arnaud Delahaye; Ali Ait Hssain; Jean Charles Chakarian; Nicolas Pichon; Arnaud Desachy; Fréderic Bellec; Didier Thevenin; Jean Pierre Quenot; Michel Sirodot; François Labadie; Gaétan Plantefeve; Dominique Vivier; Patrick Girardie; Bruno Giraudeau; Jean Reignier
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2015-03-07       Impact factor: 2.953

Review 8.  Neurocritical care update.

Authors:  Yasuhiro Kuroda
Journal:  J Intensive Care       Date:  2016-05-28

9.  The prognostic value of bispectral index and suppression ratio monitoring after out-of-hospital cardiac arrest: a prospective observational study.

Authors:  Ward Eertmans; Cornelia Genbrugge; Margot Vander Laenen; Willem Boer; Dieter Mesotten; Jo Dens; Frank Jans; Cathy De Deyne
Journal:  Ann Intensive Care       Date:  2018-03-02       Impact factor: 6.925

10.  Continuous neuromuscular blockade infusion for out-of-hospital cardiac arrest patients treated with targeted temperature management: A multicenter randomized controlled trial.

Authors:  Byung Kook Lee; In Soo Cho; Joo Suk Oh; Wook Jin Choi; Jung Hee Wee; Chang Sun Kim; Won Young Kim; Chun Song Youn
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.